(Q37415504)

20 August 2017

Bayesian adaptive randomization designs for targeted agent development (English)

1 reference

20 August 2017

J Jack Lee

1

1 reference

20 August 2017

Xuemin Gu

series ordinal

2

1 reference

20 August 2017

Suyu Liu

series ordinal

3

1 reference

20 August 2017

22 June 2010

1 reference

20 August 2017

1 reference

20 August 2017

7

1 reference

20 August 2017

5

1 reference

20 August 2017

584-596

1 reference

Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Drug development in oncology: classical cytotoxics and molecularly targeted agents

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

6 September 2017

Bayesian clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Clinical trial designs for predictive marker validation in cancer treatment trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Toward a cure for chronic myeloid leukemia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Bayesian clinical trials: no more excuses.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

2 September 2018

Adaptive trial design.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Introduction to Bayesian methods II: fundamental concepts.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Introduction to Bayesian methods I: measuring the strength of evidence.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Challenges of recruitment and retention in multisite clinical research.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Ethical issues in oncology biostatistics.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5110207

Personalized medicine: a paradigm for a sustainable pharmaceutical industry?

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20571130

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

On the efficiency of targeted clinical trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20571130

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Evaluating the efficiency of targeted designs for randomized clinical trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20571130

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1740774510373120

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

20571130

1 reference